Clinical trials: Meal Time
Diabetes, Diabetes Mellitus, Type 2
Safety and Efficacy of Insulin Aspart in Type 2 Diabetes
This trial is conducted in Japan. The aim of this trial is to investigate the safety and efficacy of NovoRapid® (insulin aspart) as meal time insulin in subjects with type 2 diabetes treated on a basal-bolus regimen with Neutral…
- Trial name
- NCT01649570
- Testing
- insulin aspart
- Where
- Japan
- Volunteers
- 123 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 1
Safety and Efficacy of Insulin Detemir Plus Insulin Aspart Against Insulin Glargine Plus Insulin Aspart as Mealtime Insulin in Type 1 Diabetes
This trial is conducted in Europe and the United States of America (USA). The purpose of this study is to test whether insulin detemir is a safe and at least as effective alternative to insulin glargine for the control of blood…
- Trial name
- NCT00095082
- Testing
- insulin detemir, insulin glargine, insulin aspart
- Where
- 81 sites in United States, Finland and 5 more
- Volunteers
- 447 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
A Study of GZR18 Tablet in Chinese Healthy Subjects
The aim of the trial is to investigate the the bioavailability, pharmacokinetics, pharmacodynamics, safety and tolerance of single and multiple doses of GZR18 tablet in healthy subjects.
- Trial name
- NCT06554054
- Testing
- GZR18
- Where
- China
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- Gan and Lee Pharmaceuticals, USA
Diabetes Mellitus
A Study Comparing the Pharmacodynamic Properties of Insulin VIAJECT™, Regular Human Insulin, and Insulin Lispro
Evaluation of post-prandial blood glucose excursions after a standardized meal and pre meal injections of individual doses of the study insulins.
- Trial name
- NCT01000922
- Testing
- Regular Human Insulin, Lispro, VIAject
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Biodel
Diabetes, Diabetes Mellitus, Type 2
A 26-week Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart BID and Insulin Degludec OD Plus Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin in Need of Treatment Intensification With Mealtime Insulin
This trial is conducted in Africa, Europe and the United States of America (USA). The aim of the trial is to compare the difference in change in glycosylated haemoglobin (HbA1c) between insulin degludec/insulin aspart (IDegAsp)…
- Trial name
- NCT01713530
- Testing
- insulin degludec/insulin aspart, insulin degludec, insulin aspart
- Where
- 51 sites in United States, Algeria and 3 more
- Volunteers
- 274 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes
Afrezza With Basal Combination (ABC): Afrezza® Combined With AID Pump or Insulin Degludec in Adults With Type 1 Diabetes
A phase 4 study evaluating the efficacy of mealtime control with Afrezza in combination with an automated insulin pump or insulin degludec in adult subjects with type 1 diabetes
- Trial name
- ABC (NCT05243628)
- Testing
- Afrezza (insulin human) Inhalation Powder, insulin degludec, Continuous Subcutaneous Insulin Infusion (CSII) pump with Automatic Insulin Delivery (AID)
- Where
- 2 sites in United States
- Volunteers
- 33 people
- Sponsor
- Mannkind Corporation
Healthy
Investigation Of Absorption And Pharmacokinetics Of A Single Dose Of Controlled Release Pregabalin Tablet Administered Fasted At Bedtime Or Immediately Following A 400-500 or 600-750 Calorie Evening Meal As Compared To Single Dose Of Immediate Release Pregabalin Capsule In Healthy Volunteers
The purpose of this study is to 1) evaluate the extent of absorption of a single dose of a pregabalin controlled release (CR) tablet administered a) fasted at bedtime, b) immediately following a 400 to 500 calorie evening meal…
- Trial name
- NCT01291524
- Testing
- Pregabalin controlled release, 330 mg, 400 to 500 calorie, Pregabalin controlled release, 330 mg, 600- 750 calorie, Pregabalin controlled release, 330 mg, bedtime
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Diabetes, Diabetes Mellitus, Type 1
A Trial Investigating the Efficacy and Safety of Insulin Degludec/Insulin Aspart Once Daily Plus Insulin Aspart for the Remaining Meals Versus Insulin Detemir Once or Twice Daily Plus Meal Time Insulin Aspart in Children and Adolescents With Type 1 Diabetes Mellitus
This trial is conducted in Asia, Europe and North and South America. The aim of the trial is to investigate the efficacy and safety of insulin degludec/insulin aspart once daily plus insulin aspart for the remaining meals in…
- Trial name
- NCT01835431
- Testing
- insulin degludec/insulin aspart, insulin aspart, insulin detemir
- Where
- 73 sites in United States, Belgium and 13 more
- Volunteers
- 362 people
- Sponsor
- Novo Nordisk A/S